Lung Cancer: How Well We Have Fared?
DOI:
https://doi.org/10.35652/IGJPS.2022.12007Keywords:
Adenocarcinoma, Chemotherapy, EGFR, Lung cancer, Driver mutationsAbstract
Lung Cancer has been one of the most common causes of death worldwide. With the death toll increasing in millions every year globally it has become a global scourge. With poor prognosis and disappointing 5 years survival rate post diagnosis, treatment for this disease has been ambiguous. Various advances in treatment are being made but till date the 5 years survival for major patients remains a dream. This review encompasses different treatment options that are available, problems associated with treatment and future perspective for the treatment of lung cancer. © 2022 iGlobal Research and Publishing Foundation. All rights reserved.
Metrics
Metrics Loading ...
Downloads
Published
2022-01-31
How to Cite
Patil, P. S., & Mahajan, H. S. (2022). Lung Cancer: How Well We Have Fared?. Indo Global Journal of Pharmaceutical Sciences (IGJPS), 12, 82–91. https://doi.org/10.35652/IGJPS.2022.12007
Issue
Section
Articles